GNH USA

Europe — EMA

Meropenem Fresenius Kabi (Meropenem Anhydrous)

GNH USA supplies Meropenem Fresenius Kabi (Meropenem), a carbapenem antibiotic for severe hospital‑acquired infections. Request a quote for global supply.

Meropenem Anhydrous

Request sourcing

1
Pack/s

What is Meropenem Anhydrous?

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as a sterile intravenous solution for intravenous use. It treats severe bacterial infections in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

What is Meropenem Anhydrous used for?

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting.

Complicated intra‑abdominal infections: effective bacterial eradication in patients with intra‑abdominal sepsis. Complicated urinary tract infections: clears resistant uropathogens in complicated cases. Hospital‑acquired pneumonia: provides coverage against multidrug‑resistant organisms. Ventilator‑associated pneumonia: treats ventilator‑related lung infections. Septicemia: rapidly reduces bloodstream bacterial load. Other severe infections caused by susceptible bacteria: used when pathogens are known to be meropenem‑sensitive.

What are the side effects of Meropenem Anhydrous?

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring in many patients. - Diarrhea: may be mild to moderate and self‑limiting. - Rash or pruritus: skin reactions ranging from mild erythema to urticaria. - Headache: transient headache reported during therapy. - Elevated liver enzymes: transient increases in ALT/AST. - Injection site phlebitis: irritation at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: may lead to colitis. - Renal toxicity: acute kidney injury in predisposed individuals. - Hematologic abnormalities: thrombocytopenia or neutropenia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

What precautions apply to Meropenem Anhydrous?

Meropenem should be used with caution in specific clinical situations.

Renal function: adjust dose in patients with impaired renal clearance. Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. Seizure risk: monitor patients with a history of seizures or CNS disorders. Pregnancy: consider only if the potential benefit outweighs the risk to the fetus. Drug interactions: review concomitant medications for possible interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Meropenem Anhydrous interact with?

Meropenem may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk. - Probenecid: may increase meropenem plasma concentrations, raising toxicity potential. - Cytotoxic agents (e.g., cyclophosphamide): heightened neurotoxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate renal impairment. - Anticoagulants (warfarin): possible alteration of INR values. - Oral contraceptives: reduced efficacy, consider alternative contraception.

Frequently asked questions

What infections is Meropenem Fresenius Kabi used to treat?+
Meropenem Fresenius Kabi is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, septicemia, and other serious infections caused by meropenem‑susceptible organisms.
How does Meropenem work against bacteria?+
Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to weakened cell walls, osmotic instability, and ultimately bacterial cell lysis and death.
What is the usual dose of Meropenem Fresenius Kabi?+
The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and susceptibility of the pathogen. No standard dose is provided here.
Is Meropenem safe to use during pregnancy or breastfeeding?+
Safety data are limited. Meropenem should be used during pregnancy or lactation only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.
How do I order Meropenem Fresenius Kabi from GNH USA?+
Submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.
How does Meropenem compare with other carbapenems?+
Meropenem offers a broad spectrum of activity similar to other carbapenems like imipenem and ertapenem, but it is less likely to cause seizures and has a more favorable renal safety profile. Choice among carbapenems depends on local resistance patterns, dosing convenience, and individual patient factors.
What are the storage and handling requirements for Meropenem Fresenius Kabi?+
The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. Once reconstituted, use within the time frame specified in the product labeling and keep the solution protected from contamination.
How is Meropenem administered to patients?+
Meropenem is given intravenously, typically as a short infusion over 15‑30 minutes. The exact infusion rate and schedule are determined by the treating physician based on the infection being treated and patient-specific factors.
What are the most serious risks associated with Meropenem therapy?+
Serious risks include severe allergic reactions (anaphylaxis), seizures (especially in patients with renal impairment or CNS disorders), Clostridioides difficile‑associated colitis, and significant renal or hematologic toxicity. Prompt medical attention is required if any of these occur.
Who should not receive Meropenem Fresenius Kabi?+
Patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking interacting drugs without appropriate monitoring.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Meropenem Anhydrous
Route
Intravenous Use
Manufacturer
Fresenius Kabi Nederland B.V.
Origin
EU

Related products

Agenor

Agenor

Meropenem Anhydrous

Medochemie Ltd.
EU
Agenorem

Agenorem

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU